Raj Satkunasivam, MD, MS, FRCSC

GU Oncology Now

Raj Satkunasivam, MD, MS, FRCSC, of Houston Methodist Hospital, explains how muscle-invasive bladder cancer (MIBC) is traditionally approached, the current momentum for an immunotherapy-plus-radiation strategy, and how previous research has led to the development and testing of the PD-1 monoclonal antibody sasanlimab in this setting.Dr. Satkunasivam is the lead investigator of the RAD VACCINE MIBC trial, a phase 2 clinical trial of neoadjuvant sasanlimab and stereotactic body radiation therapy as an in situ vaccine for cisplatin-ineligible MIBC.View Dr. Satkunasivam&rsquo;s <a href="https://guoncologynow.com/post/dr-raj-satkunasivam-on-neoadjuvant-sasanlimab-and-sbrt-for-cisplatin-ineligible-mibc" target="_blank" rel="noopener">further comments</a>.

Dr. Raj Satkunasivam on MIBC Neoadjuvant Approaches for Local, Distant Control

Muscle Invasive Urothelial Carcinoma

Dr. Satkunasivam explains how MIBC is approached, the momentum for an immunotherapy-plus-radiation strategy, and the testing of sasanlimab in this setting.

Dr. Raj Satkunasivam on MIBC Neoadjuvant Approaches

About Us

Contributors and Partners

Editorial Policy

Advertising

eNewsletters

Calendar

Contact Us

Contribute

MashupMD

Cancer Nursing Today

Urban Health Today

Blood Cancers Today

DocWire News

Knowledge Hubs

Conference Coverage

Roundtables

The Uromigos

Uromigos Live 2024

AUC3

Localized

mHSPC/mCSPC

CRPC

Diagnostics

Prostate Cancer

Localized Renal Cell Carcinoma

Advanced Renal Cell Carcinoma

nccRCC

Renal Cell Carcinoma

Non-Muscle Invasive Urothelial Carcinoma

Advanced Urothelial Carcinoma

Upper Tract Urothelial Carcinoma

Urothelial Carcinoma

Testicular, Penile, and Rare Cancers

Video Insights

Advancements in Oncology

The Oncology Brothers

Expert Interviews

Journal

Subscribe